NEW YORK (GenomeWeb) – Biodesix announced today that it has chosen Progenetics to market and distribute its liquid biopsy tests in Israel.
Under the terms of the agreement, Tel Aviv-based Progenetics will market and distribute Biodesix’s GeneStrat and VeriStrat tests, which are available for clinical use in patients with non-small cell lung cancer (NSCLS).
Get the full story This story is free
for registered users
Registering provides access to this and other free content.
Already have an account?
.
Be the first to comment